Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 385 people across nine treatment groups, all receiving different combinations of immunotherapy drugs (nivolumab, ipilimumab, and others) for colorectal cancer. The trial was measuring what is called the "objective response rate" — that is, the percentage of participants whose tumours shrank by a meaningful amount or disappeared entirely, based on standardised imaging measurements. It is noted that zero participants were recorded as having "completed" the study in the formal sense, meaning all participants fell into the "not completed" category, though no further explanation for this is provided in the reported data. The reported data shows that response rates varied widely depending on which treatment group participants were in. For the primary measure (assessed by the treating doctors), the reported rates ranged from 0% up to 71.1%. Specifically: Cohort 1 (nivolumab alone) reported 40.5%; Cohort 2 (nivolumab + ipilimumab) reported 66.4%; Cohort 3 (a different nivolumab + ipilimumab schedule) reported 71.1%; Cohort 4 (nivolumab + ipilimumab + cobimetinib) reported 3.3%; Cohort 5 (nivolumab + BMS-986016) reported 50.0%; and Cohort 6 (nivolumab + daratumumab) reported 0%. Three sub-groups reported 0%, 0%, and 10.0% respectively. A second, independent review of the same scans (the secondary outcome) produced broadly similar but not identical figures across the six cohorts for which that data was reported. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 38821718) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Colorectal Cancer Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are generally active and able to carry out daily activities with little to no limitation (confirm with trial site for exact fitness level required)
- You have been diagnosed with colorectal cancer that has come back or spread to other parts of the body, confirmed by a tissue test
- Your cancer can be measured on a scan using standard guidelines
- Your cancer has tested positive for a specific genetic feature called "microsatellite instability," confirmed by an approved laboratory
- If joining a specific group within the trial (called Cohort C3), you must not have received any treatment yet for your cancer after it spread
Who may not be able to join:
- Your cancer has spread to the brain or the lining around the brain or spinal cord
- You have previously received certain types of immunotherapy drugs that target the immune system's "checkpoint" pathways (such as anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 treatments)
- You have had another cancer that was active in the last 3 years, unless it was a type that can be completely cured with local treatment
- You currently have an active autoimmune disease (a condition where your immune system attacks your own body)
- You are currently taking steroid medicines or other drugs that suppress your immune system and have been within the last 14 days before starting the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.